Front Cover: Cholinesterase Inhibitory Activity and Molecular Docking Studies of Isocryptolepine-Triazole Adducts (ChemMedChem 24/2024)

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2024-12-16 DOI:10.1002/cmdc.202482401

Jumreang Tummatorn, Ittipat Meewan, Nisachon Khunnawutmanotham, Nitirat Chimnoi, Nutchapong Suwanwong, Warabhorn Rodphon, Charnsak Thongsornkleeb, Jingyue Yang, Somsak Ruchirawat

{"title":"Front Cover: Cholinesterase Inhibitory Activity and Molecular Docking Studies of Isocryptolepine-Triazole Adducts (ChemMedChem 24/2024)","authors":"Jumreang Tummatorn, Ittipat Meewan, Nisachon Khunnawutmanotham, Nitirat Chimnoi, Nutchapong Suwanwong, Warabhorn Rodphon, Charnsak Thongsornkleeb, Jingyue Yang, Somsak Ruchirawat","doi":"10.1002/cmdc.202482401","DOIUrl":null,"url":null,"abstract":"<p>This illustration depicts the molecular interactions of isocryptolepine-triazole hybrids with Acetylcholinesterase (AChE) in the brain related to Alzheimer′s disease. Central to the image is AChE, an enzyme involved in neurotransmitter regulation. Surrounding AChE are potential new compounds designed to inhibit its activity, thereby enhancing cholinergic signaling and potentially alleviating symptoms of Alzheimer′s. The visual emphasizes the innovative research aimed at developing effective therapeutics for this progressive neurodegenerative disorder. More details can be found in article 10.1002/cmdc.202400447 by Jumreang Tummatorn, Nutchapong Suwanwong, and co-workers.<figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"19 24","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202482401","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202482401","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

This illustration depicts the molecular interactions of isocryptolepine-triazole hybrids with Acetylcholinesterase (AChE) in the brain related to Alzheimer′s disease. Central to the image is AChE, an enzyme involved in neurotransmitter regulation. Surrounding AChE are potential new compounds designed to inhibit its activity, thereby enhancing cholinergic signaling and potentially alleviating symptoms of Alzheimer′s. The visual emphasizes the innovative research aimed at developing effective therapeutics for this progressive neurodegenerative disorder. More details can be found in article 10.1002/cmdc.202400447 by Jumreang Tummatorn, Nutchapong Suwanwong, and co-workers.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.